JP2018519508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519508A5 JP2018519508A5 JP2017562628A JP2017562628A JP2018519508A5 JP 2018519508 A5 JP2018519508 A5 JP 2018519508A5 JP 2017562628 A JP2017562628 A JP 2017562628A JP 2017562628 A JP2017562628 A JP 2017562628A JP 2018519508 A5 JP2018519508 A5 JP 2018519508A5
- Authority
- JP
- Japan
- Prior art keywords
- gitr
- time point
- seq
- tumor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170579P | 2015-06-03 | 2015-06-03 | |
| US62/170,579 | 2015-06-03 | ||
| PCT/US2016/035514 WO2016196792A1 (en) | 2015-06-03 | 2016-06-02 | Anti-gitr antibodies for cancer diagnostics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519508A JP2018519508A (ja) | 2018-07-19 |
| JP2018519508A5 true JP2018519508A5 (enExample) | 2019-06-27 |
| JP6812364B2 JP6812364B2 (ja) | 2021-01-13 |
Family
ID=56194564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562628A Expired - Fee Related JP6812364B2 (ja) | 2015-06-03 | 2016-06-02 | 癌診断用抗ｇｉｔｒ抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10690674B2 (enExample) |
| EP (1) | EP3304079B1 (enExample) |
| JP (1) | JP6812364B2 (enExample) |
| CN (1) | CN107743586B (enExample) |
| BR (1) | BR112017025297A2 (enExample) |
| CA (1) | CA2988115A1 (enExample) |
| EA (1) | EA201792497A1 (enExample) |
| ES (1) | ES2810856T3 (enExample) |
| MX (1) | MX2017015260A (enExample) |
| WO (1) | WO2016196792A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900668T1 (it) | 2014-06-06 | 2020-01-14 | Bristol Myers Squibb Co | Anticorpi contro il recettore per il fattore di necrosi tumorale indotto da glucocorticoidi(gitr)e loro usi |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| EP3304079B1 (en) | 2015-06-03 | 2020-06-03 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| BR112018001161A2 (pt) | 2015-07-23 | 2018-09-18 | Inhibrx Lp | proteínas de fusão de ligação a gitr multiespecíficas e multivalentes |
| WO2017068186A1 (en) | 2015-10-22 | 2017-04-27 | Ablynx Nv | Gitr agonists |
| US10281374B2 (en) * | 2015-11-04 | 2019-05-07 | Diagnostic Biosystems | Method of pretreatment of biological samples for an analyte-staining assay method |
| KR20180082563A (ko) | 2015-11-19 | 2018-07-18 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EP3589657A1 (en) * | 2017-03-03 | 2020-01-08 | Rinat Neuroscience Corp. | Anti-gitr antibodies and methods of use thereof |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| BR112019021680A2 (pt) | 2017-04-20 | 2020-05-12 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo-fármaco anti-cd25?? |
| PL3612234T3 (pl) | 2017-04-20 | 2024-09-02 | Adc Therapeutics Sa | Terapia skojarzona z koniugatem anty-AXL przeciwciało-lek |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| WO2018229222A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| AU2018287519B2 (en) | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| PE20200717A1 (es) | 2017-06-22 | 2020-07-21 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas |
| AU2018292618A1 (en) | 2017-06-27 | 2019-12-19 | Novartis Ag | Dosage regimens for anti-TIM-3 antibodies and uses thereof |
| KR20200031659A (ko) | 2017-07-20 | 2020-03-24 | 노파르티스 아게 | 항-lag-3 항체의 투여 요법 및 그의 용도 |
| KR20200055770A (ko) * | 2017-09-20 | 2020-05-21 | 메르사나 테라퓨틱스, 인코포레이티드 | Napi2b 표적 요법에 대한 반응을 예측하기 위한 조성물 및 방법 |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| CN110357958A (zh) | 2018-03-26 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用 |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| KR102873348B1 (ko) | 2018-07-10 | 2025-10-20 | 노파르티스 아게 | 3-(5-하이드록시-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 ikaros 패밀리 아연 핑거 2(ikzf2)-의존성 질환의 치료에 있어서의 이의 용도 |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| AU2019409139A1 (en) | 2018-12-21 | 2021-06-03 | Novartis Ag | Use of IL-1β binding antibodies |
| EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| US20200369762A1 (en) | 2018-12-21 | 2020-11-26 | Novartis Ag | Use of il-1beta binding antibodies |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4048285A1 (en) | 2019-10-21 | 2022-08-31 | Novartis AG | Tim-3 inhibitors and uses thereof |
| WO2021079188A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Combination therapies with venetoclax and tim-3 inhibitors |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| WO2021144657A1 (en) | 2020-01-17 | 2021-07-22 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| JP2023545359A (ja) * | 2020-09-12 | 2023-10-30 | アストラゼネカ・ユーケイ・リミテッド | 抗ｈｅｒ２抗体－薬物複合体治療のためのスコアリング方法 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| JP2025509832A (ja) | 2022-03-15 | 2025-04-11 | コンピュジェン リミテッド | Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用 |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US7247302B1 (en) | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| JP4440344B2 (ja) | 1996-08-16 | 2010-03-24 | シェーリング コーポレイション | 哺乳動物細胞表面抗原；関連試薬 |
| WO2001040464A1 (en) | 1999-11-30 | 2001-06-07 | Genentech, Inc. | Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization |
| GB9625074D0 (en) | 1996-12-02 | 1997-01-22 | Pharmacia & Upjohn Spa | Receptor belonging to the TNF/NGF receptor family |
| CA2308114A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| JP4485049B2 (ja) | 1997-11-18 | 2010-06-16 | ジェネンテック， インコーポレイテッド | Ｄｎａ１９３５５ポリペプチドという腫瘍壊死因子相同体 |
| IL137409A0 (en) | 1998-02-09 | 2001-07-24 | Genentech Inc | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| JP2003527815A (ja) | 1998-07-22 | 2003-09-24 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 細胞増殖関連分子 |
| MXPA01005169A (es) | 1998-12-01 | 2002-07-02 | Genentech Inc | Promocion o inhibicion deangiogenesis y cardiovascularizacion. |
| JP2002531092A (ja) | 1998-12-01 | 2002-09-24 | ジェネンテック・インコーポレーテッド | 腫瘍性細胞成長阻害のための組成物及び方法 |
| WO2000050459A1 (en) | 1999-02-24 | 2000-08-31 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| EP1196186B1 (en) | 1999-07-12 | 2007-10-31 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| DK1616575T3 (da) | 1999-12-23 | 2012-09-10 | Zymogenetics Inc | Fremgangsmåde til behandling af inflammation |
| DE60040240D1 (de) | 1999-12-23 | 2008-10-23 | Zymogenetics Inc | Löslicher interleukin-20 rezeptor |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| DE60121808T2 (de) | 2000-09-15 | 2007-03-29 | Zymogenetics, Inc., Seattle | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen |
| CA2440596C (en) | 2001-03-09 | 2011-05-24 | Zymogenetics, Inc. | Soluble heterodimeric cytokine receptor |
| WO2003006058A1 (en) | 2001-07-12 | 2003-01-23 | Wyeth | Cd25+ differential markers and uses thereof |
| AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
| AU2003267096B9 (en) | 2002-09-11 | 2010-11-11 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| CA2503330A1 (en) | 2002-10-29 | 2004-05-13 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2011516026A (ja) | 2002-11-26 | 2011-05-26 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| KR20060052681A (ko) | 2003-05-23 | 2006-05-19 | 와이어쓰 | Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도 |
| EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1692180B1 (en) | 2003-11-21 | 2009-11-04 | ZymoGenetics, Inc. | Anti-il-20 antibodies and binding partners and methods of using in inflammation |
| EP2374817B1 (en) | 2004-04-13 | 2017-09-06 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| AU2005302459A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| US20060099171A1 (en) | 2004-11-05 | 2006-05-11 | Masahide Tone | Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells |
| JP2008527998A (ja) * | 2005-01-19 | 2008-07-31 | ジェンザイム・コーポレイション | Ｎｓｃｌｃの診断のためのｇｉｔｒ抗体 |
| US7812135B2 (en) * | 2005-03-25 | 2010-10-12 | Tolerrx, Inc. | GITR-binding antibodies |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2006132272A1 (ja) | 2005-06-07 | 2006-12-14 | The University Of Tokyo | 抗体の作製方法 |
| KR20080032097A (ko) | 2005-06-20 | 2008-04-14 | 메다렉스, 인코포레이티드 | 씨디19 항체 및 그의 용도 |
| EP1979488A4 (en) | 2006-01-09 | 2009-05-27 | Univ California | IMMUNOSTIMULATING COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERIC RECEPTOR, AND CYTOKIN RECEPTOR ANTONISTS FOR VACCINES AND TUMOR IMMUNOTHERAPY |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| DK2099823T4 (da) | 2006-12-01 | 2022-05-09 | Seagen Inc | Målbindingsmiddelvarianter og anvendelser deraf |
| JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用 |
| KR20080105674A (ko) | 2007-05-31 | 2008-12-04 | 울산대학교 산학협력단 | 항-마우스 ｇｉｔｒｌ 단일클론 항체 또는 항-인간ａｉｔｒｌ 단일클론 항체 및 이를 유효성분으로 함유하는염증성 장질환의 예방 및 치료용 조성물 |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| SI2250279T1 (sl) | 2008-02-08 | 2016-10-28 | Medimmune, Llc | Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda |
| WO2009120922A2 (en) | 2008-03-27 | 2009-10-01 | Zymogenetics, Inc. | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
| HUE049825T2 (hu) | 2009-09-03 | 2020-10-28 | Merck Sharp & Dohme | Anti-GITR antitestek |
| JP5837821B2 (ja) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
| DK2542590T4 (da) | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
| EP3208281A1 (en) | 2010-03-29 | 2017-08-23 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
| AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
| CA2824278C (en) | 2010-12-20 | 2022-09-20 | The Rockefeller University | Modulating agonistic tnfr antibodies |
| EP2665750A1 (en) | 2011-01-17 | 2013-11-27 | Novo Nordisk A/S | Il-21 ligands |
| US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| AU2013201121A1 (en) | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| US20150073043A1 (en) * | 2012-01-19 | 2015-03-12 | Institut Pasteur Of Shanghai, Chinese Academy Of Sciences | Use of phosphorylation pathway-related factor in regulating function of regulatory t cell |
| US8945553B2 (en) | 2012-05-22 | 2015-02-03 | Bristol-Myers Squibb Company | Bispecific antibodies to IL-23 and IL-17A/F |
| KR101566538B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도 |
| PL2925350T3 (pl) | 2012-12-03 | 2019-07-31 | Bristol-Myers Squibb Company | Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| CA2943167A1 (en) | 2014-03-24 | 2015-10-01 | University Of Southampton | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| RS61678B1 (sr) | 2014-05-28 | 2021-05-31 | Agenus Inc | Anti-gitr antitela i postupci za njihovu primenu |
| SMT201900668T1 (it) | 2014-06-06 | 2020-01-14 | Bristol Myers Squibb Co | Anticorpi contro il recettore per il fattore di necrosi tumorale indotto da glucocorticoidi(gitr)e loro usi |
| AU2015327781A1 (en) | 2014-10-03 | 2017-04-20 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof |
| EP3304079B1 (en) | 2015-06-03 | 2020-06-03 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| KR20180082563A (ko) | 2015-11-19 | 2018-07-18 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
-
2016
- 2016-06-02 EP EP16731700.7A patent/EP3304079B1/en not_active Not-in-force
- 2016-06-02 BR BR112017025297-0A patent/BR112017025297A2/pt not_active Application Discontinuation
- 2016-06-02 US US15/578,874 patent/US10690674B2/en active Active
- 2016-06-02 MX MX2017015260A patent/MX2017015260A/es unknown
- 2016-06-02 ES ES16731700T patent/ES2810856T3/es active Active
- 2016-06-02 JP JP2017562628A patent/JP6812364B2/ja not_active Expired - Fee Related
- 2016-06-02 WO PCT/US2016/035514 patent/WO2016196792A1/en not_active Ceased
- 2016-06-02 CA CA2988115A patent/CA2988115A1/en not_active Abandoned
- 2016-06-02 EA EA201792497A patent/EA201792497A1/ru unknown
- 2016-06-02 CN CN201680032362.6A patent/CN107743586B/zh not_active Expired - Fee Related
-
2020
- 2020-05-08 US US16/870,006 patent/US11408889B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519508A5 (enExample) | ||
| RU2017116847A (ru) | Антитела к pd-1 | |
| NZ716369A (en) | Anti-ox40 antibodies and methods of using the same | |
| Stevenson et al. | The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia | |
| JP2015533788A5 (enExample) | ||
| US20180250338A1 (en) | Tumor infiltrating lymphocytes for treatment of cancer | |
| JP2020522261A5 (enExample) | ||
| JP2018502828A (ja) | Ｐｄ−１遮断による免疫療法の癌奏効の決定因子 | |
| RU2012109004A (ru) | Антитело против смет и его применение для определения и диагностики рака | |
| JP2017518366A5 (enExample) | ||
| AU2015265870A1 (en) | PD-L1 antibodies and uses thereof | |
| JP6530391B2 (ja) | Ｃｄ６結合パートナーの使用およびそれに基づく方法 | |
| WO2016032334A1 (en) | Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations | |
| EP3793598A1 (en) | Methods of treating cancer | |
| JP2022524216A (ja) | 持続的臨床効果のがんバイオマーカー | |
| EA201492105A1 (ru) | Иммунотерапия злокачественных опухолей путем нарушения передачи сигналов pd-1/pd-l1 | |
| JP2021500916A5 (enExample) | ||
| JP2015530868A5 (enExample) | ||
| CN115087749A (zh) | 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 | |
| JP2020510409A5 (enExample) | ||
| JP2014523920A5 (enExample) | ||
| JP2016502091A5 (enExample) | ||
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma | |
| WO2025042607A1 (en) | Modulation of pglyrp1 for treatment of cancer and autoimmunity | |
| Kawashiri et al. | Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index |